Direct and Indirect Thermogenic Effects of Anorectic Drugs

1985 ◽  
pp. 187-201 ◽  
Author(s):  
David A. Levitsky ◽  
Barbara J. Strupp
Keyword(s):  
Anorectic Drugs

Behavioral neurotoxicity in adolescent and adult mice exposed to fenproporex during pregnancy

2005 ◽  
Vol 24 (8) ◽  
pp. 403-408 ◽  
Author(s):  
C Q Moreira ◽  
M JSS Faria ◽  
E G Moreira
Keyword(s):  
Forced Swimming Test ◽  
Tail Suspension Test ◽  
Stereotyped Behavior ◽  
Dopaminergic Transmission ◽  
Adult Mice ◽  
Gestational Exposure ◽  
Behavioral Toxicity ◽  
Anorectic Drugs ◽  
Swimming Test ◽  
First Time

We investigated the effects of gestational exposure to fenproporex, one of the most used anorectic drugs in Brazil, on the behavior of adolescent and adult pups (30 and 60 days of age, respectively). Pregnant Swiss mice were treated daily, by gavage, with 15 mg/kg of fenproporex chloride or water during the whole gestational period. Male pups were submitted to open-field, forced swimming test, tail suspension test and fenproporexinduced stereotyped behavior. The results demonstrated that gestational exposure to fenproporex induces antidepressant-like effect and decreases fenproporexinduced stereotyped behavior in both adolescent and adult pups. Moreover, fenproporex-exposed adolescent pups tended (P–0.06) to be more active than control pups. Our data show, for the first time, that gestational exposure to fenproporex leads to long-lasting behavioral toxicity in male mice characteristic of altered dopaminergic transmission.

Anorectic Drugs and the Vasculature

2001 ◽  
pp. 837-852
Author(s):  
Evangelos D. Michelakis ◽  
E. Kenneth Weir
Keyword(s):  
Anorectic Drugs

scholarly journals Impact of health legislation on the sale of anorectics in a city in the Amazon region

2012 ◽  
Vol 42 (2) ◽  
pp. 215-220 ◽  
Author(s):  
Luana Valéria da Silva Castro ◽  
Gilvo Farias Junior ◽  
Francisco Martins Teixeira ◽  
José Ricardo dos Santos Vieira ◽  
Cristiane do Socorro Ferraz Maia
Keyword(s):  
Annual Report ◽  
Health Surveillance ◽  
Amazon Region ◽  
Balance Sheets ◽  
Department Of Health ◽  
Anorectic Drugs ◽  
Brazilian Amazon Region ◽  
Narcotics Control ◽  
Health Legislation ◽  
The Impact

OBJECTIVES: The International Narcotics Control Board released its 2005 annual report, highlighting the Brazil population as one of the largest consumers of anorectics. In Brazil, the National Health Surveillance Agency issued the resolution RDC 58/2007 in order to control the prescription and sale of such drugs. In Belém, the biggest city in the Brazilian Amazon region, this resolution came into force in 2008, leading to inspections of drugstores and magistral pharmacies. The aim of this work was to evaluate the consumption of psychotropic anorectic drugs and the impact of RDC 58/2007 on the prescription and dispensing of anorectics in drugstores and magistral pharmacies in Belém. METHODOLOGY: A retrospective quantitative and descriptive study was conducted of records from the Municipal Department of Health Surveillance of Belém, for 2005 to 2008. The differences in findings were regarded significant when p < 0.05. RESULTS: A total of 1,641 balance sheets of drugstores and magistral pharmacies were analyzed. Amfepramone was the most dispensed medication, followed by fenproporex and mazindol. The highest consumption of anorectics occurred in magistral pharmacies. In 2008, there was a significant reduction in dispensing of anorectics, in drugstores as well as in magistral pharmacies. CONCLUSIONS: This study showed that there was a decrease in the dispensing of anorectics after RDC 58/2007 came into force, and that the magistral pharmacies dispensed more of these drugs. This resolution is a remarkable tool in health control, where it is of great benefit to public health and contributes substantially to the rational use of medicines in Brazil.

scholarly journals Dexfenfluramine and Pergolide Cause Heart Valve Disease via Valve Metabolic Reprogramming and Ongoing Matrix Remodeling

2020 ◽  
Vol 21 (11) ◽  
pp. 4003
Author(s):  
Cécile Oury ◽  
Patrick Maréchal ◽  
Nathalie Donis ◽  
Alexia Hulin ◽  
Alexandre Hego ◽  
...  
Keyword(s):  
Energy Homeostasis ◽  
Cell Metabolism ◽  
Transcriptome Profiling ◽  
Metabolic Reprogramming ◽  
Heart Valve Disease ◽  
High Dose ◽  
Matrix Remodeling ◽  
Cell Matrix ◽  
Anorectic Drugs ◽  
Cell Energy

Several clinical reports indicate that the use of amphetaminic anorectic drugs or ergot derivatives could cause valvular heart disease (VHD). We sought to investigate whether valvular lesions develop in response to long-term oral administration of these drugs and to identify drug-targeted biological processes that may lead to VHD. Treatment of New Zealand White rabbits with pergolide, dexfenfluramine, or high-dose serotonin for 16 weeks induced valvular alterations characterized by extracellular matrix remodeling. Transcriptome profiling of tricuspid valves using RNA sequencing revealed distinct patterns of differentially expressed genes (DEGs) that clustered according to the different treatments. Genes that were affected by the three treatments were functionally enriched for reduced cell metabolism processes. The two drugs yielded more changes in gene expression than serotonin and shared most of the DEGs. These DEGs were mostly enriched for decreased biosynthetic processes, increased cell-matrix interaction, and cell response to growth factors, including TGF-β, which was associated with p38 MAPK activation. Treatment with pergolide specifically affected genes involved in homeostasis, which was corroborated by the activation of the master regulator of cell energy homeostasis, AMPK-α, as well as decreased levels of metabolism-related miR-107. Thus, both pergolide and dexfenfluramine may cause VHD through valve metabolic reprogramming and matrix remodeling.

PERIPHERAL EFFECTS OF ANORECTIC DRUGS

The Lancet ◽  
1976 ◽  
Vol 307 (7961) ◽  
pp. 691-692 ◽  
Author(s):  
J.S. Garrow
Keyword(s):  
Anorectic Drugs

Developmental exposure to fenproporex: reproductive and morphological evaluation

2005 ◽  
Vol 24 (8) ◽  
pp. 397-402 ◽  
Author(s):  
C Q Moreira ◽  
M JSS Faria ◽  
J E Baroneza ◽  
R J Oliveira ◽  
E G Moreira
Keyword(s):  
Gravid Uterus ◽  
Maternal Weight ◽  
Developmental Exposure ◽  
Morphological Evaluation ◽  
Anorectic Drugs ◽  
Significant Difference ◽  
Uterine Growth ◽  
Teratogenic Potential ◽  
C 30 ◽  
Cervical Ribs

This study was designed to evaluate the maternal toxicity and teratogenicity of fenproporex, one of the most widelyused anorectic drugs in many countries, including Brazil. Three periods of exposure were evaluated: (a) 30 days before mating; (b) from gestational day (GD) 0 to 14; and (c) 30 days before mating and during pregnancy, until GD 14. Female mice from experimental groups received, by gavage, 15 mg/kg of fenproporex. Treatment with fenproporex increased ambulation of dams in the open field test and did not influence the mobility in the forcedswimming test. There was no significant difference in maternal weight gain between the controls and fenproporex-treated groups, although fenproporex treatment reduced the gravid uterus weight. No significant difference was observed in postimplantation loss, fetal viability and sex ratio. In addition, this compound did not impair intra-uterine growth. The reduction in the number of implantations in the groups receiving fenproporex indicates that this drug may have an adverse effect on implantation. Fenproporex treatment also increased the number of fetuses presenting small kidneys and cervical ribs. The present results indicate that fenproporex, in the dose and exposure periods tested, appears to exhibit a low maternal toxicity and teratogenic potential in mice.

Sign in / Sign up

Export Citation Format

Share Document